Transgene Aktie

0,6240 EUR ±0,0000 EUR ±0,00 %

11.04.2025

STU

0,6420 EUR +0,0300 EUR +4,90 %

10.04.2025

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.83,65 Mio. EUR

Div. Rendite0,00%

WKN913048

ISINFR0005175080

SymbolTRGNF

Transgene Aktien News

Sortieren:Datum Meistgelesen

10.10.23BusinesswireTransgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)

20.09.23BusinesswireTransgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024

14.09.23BusinesswireTransgene Announces Upcoming Investor Meetings

17.07.23BusinesswireTransgene Receives $15.3 Million from the Sale of Securities Held for Sale

06.06.23BusinesswireTransgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

05.06.23BusinesswireTransgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

25.05.23BusinesswireTransgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors

10.05.23BusinesswireTransgene provides business update and Q1 2023 financial position

10.05.23BusinesswireTransgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer

05.05.23BusinesswireTransgene’s Combined General Meeting of May 5, 2023

05.05.23BusinesswireTransgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio

18.04.23BusinesswireNew Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023

17.04.23BusinesswireTransgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

12.04.23BusinesswireTransgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director

11.04.23BusinesswireTransgene: Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023

04.04.23BusinesswireTransgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers

27.03.23BusinesswireTransgene Announces Upcoming Investor Meetings

16.03.23BusinesswireTransgene: 2022 Full-year Results and Business Update

15.03.23BusinesswireTransgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

09.03.23BusinesswireTransgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

06.01.23BusinesswireTransgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

04.01.23BusinesswireTransgene Announces Financial Calendar for 2023

15.12.22BusinesswireTransgene Announces Upcoming Investor Meetings

14.11.22BusinesswireTransgene and BioInvent Joint Paper on BT-001 Wins JITC "Best Oncolytic and Local Immunotherapy Paper” Award for 2022

07.11.22BusinesswireTransgene Reports Business Update And Q3 2022 Financial Position

02.11.22BusinesswireTransgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

27.09.22BusinesswireR&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

12.09.22BusinesswireTransgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

07.09.22BusinesswirePositive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022

31.08.22BusinesswireTransgene Announces Upcoming Investor Meetings

28.06.22BusinesswireTransgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®

27.06.22BusinesswireTransgene and BioInvent Announce Positive Progress for BT-001

06.06.22BusinesswireTransgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022

27.05.22BusinesswireTransgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022

25.05.22BusinesswireTransgene’s Combined General Meeting of May 25, 2022

17.05.22BusinesswireTransgene Announces Upcoming Investor Meetings

10.05.22BusinesswireTransgene: Q1 2022 Financial Position and Business Update

Transgene News

Transgene News: auf dieser Seite finden Sie alle Transgene News und Nachrichten zur Transgene Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Transgene News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Transgene News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.